Jump to content
RemedySpot.com

Peregrine's Bavituximab HCV Abstract Accepted for Presentation

Rate this topic

Guest guest

By Guest guest
in Health, Medicine and Natural Healing 11

 Share

Recommended Posts

Guest guest

Guest guest

Posted
Posted

Peregrine's Bavituximab HCV Abstract Accepted for Presentation

Market Wire - Mar. 07, 2011

Peregrine Pharmaceuticals today announced that data from the company's Phase Ib

dose escalation safety study of bavituximab in patients coinfected with chronic

hepatitis C virus (HCV) and HIV has been accepted for presentation at the 46th

annual meeting of the European Association for the Study of the Liver (EASL)

taking place in Berlin, Germany from March 30 to April 3, 2011.

Link to comment
Share on other sites
Guest guest

Guest guest

Posted
Posted

Peregrine's Bavituximab HCV Abstract Accepted for Presentation

Market Wire - Mar. 07, 2011

Peregrine Pharmaceuticals today announced that data from the company's Phase Ib

dose escalation safety study of bavituximab in patients coinfected with chronic

hepatitis C virus (HCV) and HIV has been accepted for presentation at the 46th

annual meeting of the European Association for the Study of the Liver (EASL)

taking place in Berlin, Germany from March 30 to April 3, 2011.

Link to comment
Share on other sites

Join the conversation

You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

Loading...
×
 Share
Go to topic listing
×
×
  • Create New...